drugset
drugset / Trial / NCT04853927

Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit

NCT04853927 ↗

Phase 3 Withdrawn Applied Biology, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of Proxalutamide as a treatment for COVID-19 patients in the intensive care unit

Timeline

Start
2021-02-08
Primary completion
2021-10-30
Completion
2021-12-31

Outcome

Outcome not reported

Stopped: “Sponsor to focus on hospitalised patients”

Drugs

EvaluationDrugModalityDoseRoute
Comparator PRUXELUTAMIDE Small molecule 300 mg —

Indications

COVID-19 severe acute respiratory syndrome